## James M Brophy

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1461006/publications.pdf

Version: 2024-02-01

8618 23544 22,936 312 58 146 citations h-index g-index papers 323 323 323 24195 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	A randomized controlled trial of renin-angiotensin-aldosterone system inhibitor management in patients admitted in hospital with COVID-19. American Heart Journal, 2022, 247, 76-89.	1.2	12
2	Pacemaker risk following transcatheter aortic valve replacement - A Bayesian reanalysis. International Journal of Cardiology, 2022, 355, 32-36.	0.8	0
3	Clinical Prediction Models for Heart Failure Hospitalization in Type 2 Diabetes: A Systematic Review and Metaâ€Analysis. Journal of the American Heart Association, 2022, 11, e024833.	1.6	7
4	Remdesivir for the treatment of COVID-19: a systematic review and meta-analysis. Clinical Microbiology and Infection, 2022, 28, 1203-1210.	2.8	50
5	Treatment and prescribing trends of antihypertensive drugs in 2.7 million UK primary care patients over 31 years: a population-based cohort study. BMJ Open, 2022, 12, e057510.	0.8	9
6	Big data, big expectations and big judgements. Canadian Journal of Cardiology, 2022, , .	0.8	0
7	Risk prediction models for heart failure admissions in adults with congenital heart disease. International Journal of Cardiology, 2021, 322, 149-157.	0.8	21
8	Distorting Effect of Immortal Time Bias on the Association Between Catheter Ablation for Atrial Fibrillation and Incident Stroke: Caveat Emptor. Canadian Journal of Cardiology, 2021, 37, 377-381.	0.8	2
9	Management of Renin-Angiotensin-Aldosterone System blockade in patients admitted to hospital with confirmed coronavirus disease (COVID-19) infection (The McGill RAAS-COVID-19): A structured summary of a study protocol for a randomized controlled trial. Trials, 2021, 22, 115.	0.7	5
10	Comparative effectiveness and safety of highâ€dose rivaroxaban and apixaban for atrial fibrillation: A propensity scoreâ€matched cohort study. Pharmacotherapy, 2021, 41, 379-393.	1.2	5
11	Remdesivir and systemic corticosteroids for the treatment of COVID-19: A Bayesian re-analysis. International Journal of Infectious Diseases, 2021, 104, 671-676.	1.5	21
12	The COVID-19 Pandemic and Coronary Angiography for ST-Elevation Myocardial Infarction, Use of Mechanical Support, and Mechanical Complications in Canada: A Canadian Association of Interventional Cardiology National Survey. CJC Open, 2021, 3, 1125-1131.	0.7	4
13	Reply to "Risk prediction models for heart failure admissions in adults with congenital heart disease: Methodological issues― International Journal of Cardiology, 2021, 333, 96.	0.8	0
14	To Adjust or Not to Adjust: The Role of Different Covariates in Cardiovascular Observational Studies. American Heart Journal, 2021, 237, 62-67.	1.2	44
15	Bayesian Analyses of Cardiovascular Trials—Bringing Added Value to the Table. Canadian Journal of Cardiology, 2021, 37, 1415-1427.	0.8	3
16	Domperidone Increases Harmful Cardiac Events in Parkinson's Disease: A Bayesian Re-Analysis of an Observational Study. Journal of Clinical Epidemiology, 2021, 140, 93-100.	2.4	0
17	Emulating a Randomised Controlled Trial With Observational Data: An Introduction to the Target Trial Framework. Canadian Journal of Cardiology, 2021, 37, 1365-1377.	0.8	20
18	Key Issues in the Statistical Interpretation of Randomized Clinical Trials. Canadian Journal of Cardiology, 2021, 37, 1312-1321.	0.8	3

#	Article	IF	Citations
19	Comparative Effectiveness and Safety of Low-Dose Oral Anticoagulants in Patients With Atrial Fibrillation. Frontiers in Pharmacology, 2021, 12, 812018.	1.6	4
20	Determinants of Survival in Older Adults With Congenital Heart Disease Newly Hospitalized for Heart Failure. Circulation: Heart Failure, 2020, 13, e006490.	1.6	12
21	Evaluation of propensity score used in cardiovascular research: a cross-sectional survey and guidance document. BMJ Open, 2020, 10, e036961.	0.8	11
22	Revascularizing Diabetic Multivessel Coronary Artery Disease in the 2020s. Journal of the American College of Cardiology, 2020, 76, 1165-1167.	1.2	1
23	Bayesian Interpretation of the EXCEL Trial and Other Randomized Clinical Trials of Left Main Coronary Artery Revascularization. JAMA Internal Medicine, 2020, 180, 986.	2.6	30
24	Risk of readmission after heart failure hospitalization in older adults with congenital heart disease. International Journal of Cardiology, 2020, 320, 70-76.	0.8	6
25	Recursive multiresolution convolutional neural networks for 3D aortic valve annulus planimetry. International Journal of Computer Assisted Radiology and Surgery, 2020, 15, 577-588.	1.7	10
26	The Dollars and Sense of Transcatheter Aortic Valve Replacement: An Example of the Benefit of Avoiding Stenoses in Health Care Services Research. Canadian Journal of Cardiology, 2020, 36, 1194-1195.	0.8	0
27	Immediate vs Delayed Stenting in ST-Elevation Myocardial Infarction: Rationale and Design of the International PRIMACY Bayesian Randomized Controlled Trial. Canadian Journal of Cardiology, 2020, 36, 1805-1814.	0.8	10
28	2018 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal, 2019, 40, 87-165.	1.0	4,537
29	2018 ESC/EACTS Guidelines on myocardial revascularization. European Journal of Cardio-thoracic Surgery, 2019, 55, 4-90.	0.6	402
30	Challenges in Assessing the Incidence of Atrial Fibrillation Hospitalizations. Canadian Journal of Cardiology, 2019, 35, 1291-1293.	0.8	2
31	A Non-inferiority Framework for Cost-Effectiveness Analysis. International Journal of Technology Assessment in Health Care, 2019, 35, 291-297.	0.2	4
32	Heart failure risk predictions in adult patients with congenital heart disease: a systematic review. Heart, 2019, 105, 1661-1669.	1.2	26
33	Mortality Benefit of Alirocumab: A Bayesian Perspective. Journal of the American Heart Association, 2019, 8, e013170.	1.6	4
34	Variability in High-Sensitivity Cardiac Troponin T Testing in Stable Patients With and Without Coronary Artery Disease. Canadian Journal of Cardiology, 2019, 35, 1505-1512.	0.8	7
35	The Reply. American Journal of Medicine, 2019, 132, e24-e25.	0.6	1
36	Oral Fluoroquinolones and RiskÂofÂMitralÂand Aortic Regurgitation. Journal of the American College of Cardiology, 2019, 74, 1444-1450.	1.2	28

#	Article	IF	CITATIONS
37	Subsequent Event Risk in Individuals With Established Coronary Heart Disease. Circulation Genomic and Precision Medicine, 2019, 12, e002470.	1.6	17
38	Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events. Circulation Genomic and Precision Medicine, 2019, 12, e002471.	1.6	22
39	Associations between ambient air pollution and daily mortality in a cohort of congestive heart failure: Case-crossover and nested case-control analyses using a distributed lag nonlinear model. Environment International, 2018, 113, 313-324.	4.8	25
40	Comparative effectiveness of novel oral anticoagulants in UK patients with non-valvular atrial fibrillation and chronic kidney disease: a matched cohort study. BMJ Open, 2018, 8, e019638.	0.8	28
41	Big Data to Assess Potential Pregnancy-Related Cardiovascular Complications of Difficult Labour—Original Investigator-Driven Research Is Not Dead!. Canadian Journal of Cardiology, 2018, 34, 6-7.	0.8	1
42	Authors' reply to commentary: Renewed controversy over cardiovascular risk with non-steroidal anti-inflammatory drugs. International Journal of Epidemiology, 2018, 47, 674-675.	0.9	0
43	Response by Labos et al to Letter Regarding Article, "Evaluation of the Pleiotropic Effects of Statins: A Reanalysis of the Randomized Trial Evidence Using Egger Regression― Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, e87-e88.	1.1	1
44	Imputation of Baseline LDL Cholesterol Concentration in Patients with Familial Hypercholesterolemia on Statins or Ezetimibe. Clinical Chemistry, 2018, 64, 355-362.	1.5	47
45	Effectiveness of Oral Bisphosphonates in Reducing Fracture Risk Among Oral Glucocorticoid Users: Three Matched Cohort Analyses. Journal of Bone and Mineral Research, 2018, 33, 419-429.	3.1	45
46	Risk of acute myocardial infarction with realâ€world <scp>NSAID</scp> s depends on dose and timing of exposure. Pharmacoepidemiology and Drug Safety, 2018, 27, 69-77.	0.9	32
47	Evaluation of the Pleiotropic Effects of Statins. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 262-265.	1.1	32
48	Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Update 2018. Canadian Journal of Cardiology, 2018, 34, 1553-1563.	0.8	105
49	Food for Thought: A "Low-Tech―Road to Improved Primary Cardiovascular Prevention: Adherence to Dietary Guidelines. Canadian Journal of Cardiology, 2018, 34, 1551-1552.	0.8	1
50	Familial hypercholesterolemia in Canada: Initial results from the FH Canada national registry. Atherosclerosis, 2018, 277, 419-424.	0.4	18
51	Guideline: 11 professional organizations made 106 recommendations for management of high blood pressure in adults. Annals of Internal Medicine, 2018, 169, JC27.	2.0	0
52	Review: In hypertension, intensive BP goals reduce CV events; self vs office BP measures do not improve BP at 12 mo. Annals of Internal Medicine, 2018, 169, JC26.	2.0	0
53	Quadrivalent human papillomavirus vaccination in girls and the risk of autoimmune disorders: the Ontario Grade 8 HPV Vaccine Cohort Study. Cmaj, 2018, 190, E648-E655.	0.9	28
54	Simplified Canadian Definition for Familial Hypercholesterolemia. Canadian Journal of Cardiology, 2018, 34, 1210-1214.	0.8	62

#	Article	IF	CITATIONS
55	Update on the Familial Hypercholesterolemia Canada (FH Canada) Registry. Atherosclerosis Supplements, 2018, 32, 51-52.	1.2	0
56	Statin medications and the risk of gynecomastia. Clinical Endocrinology, 2018, 89, 470-473.	1.2	7
57	Sodium, Chloride, and Cardiovascular Mortality—Open Access Data Is Worth Its Salt. Canadian Journal of Cardiology, 2018, 34, 968-969.	0.8	O
58	Studying additive interaction in a healthcare database: Case study of NSAIDs, cardiovascular profiles, and acute myocardial infarction. PLoS ONE, 2018, 13, e0201884.	1.1	5
59	Diastolic Hypotension May Attenuate Benefits from Intensive Systolic Targets: Secondary Analysis of a Randomized Controlled Trial. American Journal of Medicine, 2018, 131, 1228-1233.e1.	0.6	22
60	Strategies for evaluating the assumptions of the regression discontinuity design: a case study using a human papillomavirus vaccination programme. International Journal of Epidemiology, 2017, 46, dyw195.	0.9	13
61	Review: In type 2 diabetes, sodium–glucose cotransporter 2 inhibitors do not increase major CV events or mortality. Annals of Internal Medicine, 2017, 166, JC7.	2.0	0
62	Cost of Cardiac Surgery in Frail Compared With Nonfrail Older Adults. Canadian Journal of Cardiology, 2017, 33, 1020-1026.	0.8	67
63	Letter by Brophy Regarding Article, "ImPRECISION: Limitations to Interpretation of a Large Randomized Clinical Trial― Circulation, 2017, 135, e1052-e1053.	1.6	0
64	Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. Lancet Diabetes and Endocrinology,the, 2017, 5, 534-543.	5.5	84
65	What to Do Following Fibrinolysis for ST-Elevation Myocardial Infarction. JAMA Internal Medicine, 2017, 177, 1073.	2.6	0
66	Impact of Selection Bias on Estimation of Subsequent Event Risk. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	28
67	Authors' reply to Evans. BMJ: British Medical Journal, 2017, 358, j3185.	2.4	0
68	Authors' reply to Wicks. BMJ: British Medical Journal, 2017, 358, j3434.	2.4	1
69	Sharing the Process of Diagnostic Decision Making. JAMA Internal Medicine, 2017, 177, 1245.	2.6	5
70	Cardiac Resynchronization Therapy in Heart Failure: Do Evidence-Based Guidelines Follow the Evidence?. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	0.9	2
71	Differences Between Conditional and Marginal Propensity Score Estimates. Journal of the American College of Cardiology, 2017, 70, 117.	1.2	3
72	Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ: British Medical Journal, 2017, 357, j1909.	2.4	346

#	Article	IF	CITATIONS
73	Economic Evaluation of Exercise-Based Cardiac Rehabilitation Programs for Chronic Heart Failure Patients in Colombia. Journal of Cardiopulmonary Rehabilitation and Prevention, 2016, 36, 12-19.	1.2	8
74	Reply to Letter From Kroll etÂal.â€"Risk of Death With Conducted Energy Weapons. Canadian Journal of Cardiology, 2016, 32, 1261.e13.	0.8	0
75	Mortality risk of sotalol and amiodarone for post-CABG atrial fibrillation. International Journal of Cardiology, 2016, 214, 502-507.	0.8	5
76	Occurrence of pregnancy and pregnancy outcomes during isotretinoin therapy. Cmaj, 2016, 188, 723-730.	0.9	47
77	Urban–rural differences in the uptake of new oral bisphosphonate formulations. Archives of Osteoporosis, 2016, 11, 11.	1.0	2
78	Outcomes of Patients With ST-Elevation Myocardial Infarction Receiving and Not Receiving Reperfusion Therapy: The Importance of Examining All Patients. Canadian Journal of Cardiology, 2016, 32, 1325.e11-1325.e18.	0.8	8
79	Trends In Oral Glucocorticoid Utilization Among Older Adults With Respiratory Disease. Value in Health, 2016, 19, A120.	0.1	0
80	Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: a network meta-analysis. Osteoporosis International, 2016, 27, 1989-1998.	1.3	45
81	STEMI Treatment 2016: Is Outcome Improvement Stalling and If So, Why?. Canadian Journal of Cardiology, 2016, 32, 1193-1196.	0.8	0
82	Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials. Osteoporosis International, 2016, 27, 1709-1718.	1.3	106
83	Poor perception of bronchoconstriction and hyperinflation and risk of acute asthma exaerbations: A data linkage analysis. , 2016, , .		0
84	Vioxx redux $\hat{a} \in \text{``or how I learned to worry about industry-sponsored clinical trials. Indian Journal of Medical Ethics, 2016, 1, 224-226.}$	0.2	3
85	Performance of an integrated network model: Evaluation of the first 4 years. Canadian Family Physician, 2016, 62, e448-56.	0.1	0
86	Comparison of the Effect of Thiazide Diuretics and Other Antihypertensive Drugs on Central Blood Pressure: Crossâ€Sectional Analysis Among Nondiabetic Patients. Journal of Clinical Hypertension, 2015, 17, 848-854.	1.0	8
87	Transcatheter aortic valve replacement reduced mortality more than usual care in inoperable severe aortic stenosis. Annals of Internal Medicine, 2015, 163, JC4.	2.0	0
88	Transcatheter and surgical aortic valve replacement did not differ for mortality in severe aortic stenosis. Annals of Internal Medicine, 2015, 163, JC3.	2.0	0
89	Performance of the disease risk score in a cohort study with policy-induced selection bias. Journal of Comparative Effectiveness Research, 2015, 4, 607-614.	0.6	0
90	Improving the evidence base for better comparative effectiveness research. Journal of Comparative Effectiveness Research, 2015, 4, 525-535.	0.6	2

#	Article	IF	Citations
91	Physiological and perceived health effects from daily changes in air pollution and weather among persons with heart failure: A panel study. Journal of Exposure Science and Environmental Epidemiology, 2015, 25, 187-199.	1.8	30
92	Placing HPS2-THRIVE in context using Bayesian analysis. International Journal of Cardiology, 2015, 195, 203-204.	0.8	1
93	Estimating the Risk of Cardiac Mortality After Exposure to Conducted Energy Weapons. Canadian Journal of Cardiology, 2015, 31, 1439-1446.	0.8	5
94	Testosterone Therapy and Risk of Myocardial Infarction: A Pharmacoepidemiologic Study. Pharmacotherapy, 2015, 35, 72-78.	1.2	53
95	Screening Strategies and Primary Prevention Interventions in Relatives of People With Coronary Artery Disease: A Systematic Review and Meta-analysis. Canadian Journal of Cardiology, 2015, 31, 649-657.	0.8	9
96	Utility of a genetic risk score to predict recurrent cardiovascular events 1 year after an acute coronary syndrome: A pooled analysis of the RISCA, PRAXY, and TRIUMPH cohorts. Atherosclerosis, 2015, 242, 261-267.	0.4	21
97	Glucocorticoid-induced osteoporosis management among seniors, by year, sex, and indication, 1996–2012. Osteoporosis International, 2015, 26, 2845-2852.	1.3	21
98	The Early Benefits of Human Papillomavirus Vaccination on Cervical Dysplasia and Anogenital Warts. Pediatrics, 2015, 135, e1131-e1140.	1.0	58
99	Multicenter trials, guidelines, and uncertainties — Do we know as much as we think we do?. International Journal of Cardiology, 2015, 187, 600-603.	0.8	8
100	Interrupted time series analysis in drug utilization research is increasing: systematic review and recommendations. Journal of Clinical Epidemiology, 2015, 68, 950-956.	2.4	318
101	Effect of human papillomavirus (HPV) vaccination on clinical indicators of sexual behaviour among adolescent girls: the Ontario Grade 8 HPV Vaccine Cohort Study. Cmaj, 2015, 187, E74-E81.	0.9	86
102	Risperidone and Risk of Gynecomastia in Young Men. Journal of Child and Adolescent Psychopharmacology, 2015, 25, 671-673.	0.7	11
103	Stroke in Adults With Congenital Heart Disease. Circulation, 2015, 132, 2385-2394.	1.6	140
104	Risks of Cardiac Valve Regurgitation and Heart Failure Associated with Ergot- and Non-Ergot-Derived Dopamine Agonist Use in Patients with Parkinson's Disease: A Systematic Review of Observational Studies. CNS Drugs, 2015, 29, 985-998.	2.7	37
105	Impact of ECG Findings and Process-Of-Care Characteristics on the Likelihood of Not Receiving Reperfusion Therapy in Patients with ST-Elevation Myocardial Infarction: Results of a Field Evaluation. PLoS ONE, 2014, 9, e104874.	1.1	10
106	Traditional risk factors and a Genetic Risk Score are associated with age of first acute coronary syndrome. Heart, 2014, 100, 1620-1624.	1.2	16
107	Statistical problems with study on milk intake and mortality and fractures. BMJ, The, 2014, 349, g6991-g6991.	3.0	6
108	Door-to-Balloon Time and Mortality. New England Journal of Medicine, 2014, 370, 178-182.	13.9	11

#	Article	IF	CITATIONS
109	Coronary Revascularization in Diabetic Patients. Annals of Internal Medicine, 2014, 161, 724.	2.0	21
110	Canadian Cardiovascular Society Position Statement onÂFamilial Hypercholesterolemia. Canadian Journal of Cardiology, 2014, 30, 1471-1481.	0.8	93
111	Evidence of effective delivery of the human papillomavirus (HPV) vaccine through a publicly funded, school-based program: the Ontario Grade 8 HPV Vaccine Cohort Study. BMC Public Health, 2014, 14, 1029.	1.2	7
112	Individual- and Regional-level determinants of Human Papillomavirus (HPV) vaccine refusal: the Ontario Grade 8 HPV vaccine cohort study. BMC Public Health, 2014, 14, 1047.	1.2	25
113	Long-term cost-effectiveness of transcatheter versus surgical closure of secundum atrial septal defect in adults. International Journal of Cardiology, 2014, 172, 109-114.	0.8	41
114	Longitudinal trends in sFas, a biomarker of apoptosis, after an acute coronary syndrome: Clues to the pathogenesis underlying adverse events on follow-up. International Journal of Cardiology, 2014, 173, 603-607.	0.8	1
115	Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis. Osteoporosis International, 2014, 25, 1225-1235.	1.3	44
116	Antibiotics and sudden death in adults taking renin-angiotensin system blockers. BMJ, The, 2014, 349, g6242-g6242.	3.0	1
117	Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis—reply to Pazianas and Abrahamsen. Osteoporosis International, 2014, 25, 2671-2672.	1.3	10
118	Oral fluoroquinolone use and risk of peripheral neuropathy. Neurology, 2014, 83, 1261-1263.	1.5	89
119	Fish Oil for the Reduction of Atrial Fibrillation Recurrence, Inflammation,Âand Oxidative Stress. Journal of the American College of Cardiology, 2014, 64, 1441-1448.	1.2	76
120	ACC/AHA/ASE/ASNC/HRS/IAC/Mended Hearts/NASCI/RSNA/SAIP/SCAI/SCCT/SCMR/SNMMI 2014 Health Policy Statement on Use of Noninvasive Cardiovascular Imaging. Journal of the American College of Cardiology, 2014, 63, 698-721.	1.2	47
121	Risperidone Use and Risk for Gynecomastia in Men. Journal of Clinical Psychopharmacology, 2014, 34, 656-657.	0.7	2
122	A systematic review and meta-analysis of surgical outcomes following mitral valve surgery in octogenarians: implications for transcatheter mitral valve interventions. EuroIntervention, 2014, 9, 1225-1234.	1.4	33
123	Fibrinolysis or Primary PCI in Myocardial Infarction. New England Journal of Medicine, 2013, 369, 279-281.	13.9	7
124	Isotretinoin and Risk for Inflammatory Bowel Disease. JAMA Dermatology, 2013, 149, 216.	2.0	81
125	Polycystic ovary syndrome and combined oral contraceptive use: a comparison of clinical practice in the United States to treatment guidelines. Gynecological Endocrinology, 2013, 29, 365-369.	0.7	17
126	Development of a Genetic Risk Score to Predict Adverse Outcomes After ACS. Canadian Journal of Cardiology, 2013, 29, S292.	0.8	0

#	Article	IF	Citations
127	Costs associated with hospital admission for heart failure in two hospitals in the city of bogota, Colombia. Value in Health, 2013, 16, A190.	0.1	1
128	Revascularization Techniques in Diabetics - A (Network) Meta-Analysis in Progress. Canadian Journal of Cardiology, 2013, 29, S282-S283.	0.8	0
129	Estimating the costs of cardiac rehabilitation programs in heart failure (HF) in colombia: construction based on expert consensus. Value in Health, 2013, 16, A283.	0.1	0
130	Associations between ambient air pollution and daily mortality among elderly persons in Montreal, Quebec. Science of the Total Environment, 2013, 463-464, 931-942.	3.9	113
131	Male Breast Cancer and 5α-Reductase Inhibitors Finasteride and Dutasteride. Journal of Urology, 2013, 190, 1811-1814.	0.2	34
132	Drospirenone and non-fatal venous thromboembolism: is there a risk difference by dosage of ethinyl-estradiol?. Journal of Thrombosis and Haemostasis, 2013, 11, 1059-1068.	1.9	16
133	Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis. Cmaj, 2013, 185, E115-E120.	0.9	89
134	Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology. BMJ, The, 2013, 347, f6320-f6320.	3.0	73
135	Risk of acute kidney injury associated with the use of fluoroquinolones. Cmaj, 2013, 185, E475-E482.	0.9	71
136	Defining, quantifying, and characterizing adult frequent users of a suburban Canadian emergency department. Canadian Journal of Emergency Medicine, 2013, 15, 214-226.	0.5	44
137	A randomized trial of two home-based exercise programmes to improve functional walking post-stroke. Clinical Rehabilitation, 2013, 27, 659-671.	1.0	53
138	Educating the Adolescent and Young Adult With Cystic Fibrosis About Their Reproductive Risks and Options: Response. Chest, 2013, 143, 580.	0.4	1
139	Time Variability of C-Reactive Protein: Implications for Clinical Risk Stratification. PLoS ONE, 2013, 8, e60759.	1.1	42
140	Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants, Prolactin and Breast Cancer. Frontiers in Oncology, 2012, 2, 177.	1.3	20
141	Adjusting for Partial Verification or Workup Bias in Meta-Analyses of Diagnostic Accuracy Studies. American Journal of Epidemiology, 2012, 175, 847-853.	1.6	23
142	Retinal Detachment and Fluoroquinolonesâ€"Reply. JAMA - Journal of the American Medical Association, 2012, 308, 233.	3.8	1
143	Oral Fluoroquinolones and the Risk of Retinal Detachment. JAMA - Journal of the American Medical Association, 2012, 307, 1414.	3.8	163
144	Drug-Eluting Stents in ST-Segment Elevation Myocardial Infarction. Archives of Internal Medicine, 2012, 172, 621.	4.3	4

#	Article	IF	Citations
145	Bronchodilator Use and the Risk of Arrhythmia in COPD. Chest, 2012, 142, 298-304.	0.4	49
146	Bronchodilator Use and the Risk of Arrhythmia in COPD. Chest, 2012, 142, 305-311.	0.4	87
147	A network meta-analysis of antibiotics for treatment of hospitalised patients with suspected or proven meticillin-resistant Staphylococcus aureus infection. International Journal of Antimicrobial Agents, 2012, 40, 479-495.	1.1	25
148	Review: Low-quality evidence fails to show that antihypertensive drugs affect outcomes in mild hypertension. Annals of Internal Medicine, 2012, 157, JC6.	2.0	1
149	Irritable Bowel Syndrome and Drospirenone-Containing Oral Contraceptives; A Comparative-Safety Study. Current Drug Safety, 2012, 7, 8-15.	0.3	7
150	Dopamine agonist use and the risk of heart failure. Pharmacoepidemiology and Drug Safety, 2012, 21, 34-41.	0.9	36
151	Antipsychotic Drugs and the Risk of Hyperglycemia in Older Adults Without Diabetes: A Population-Based Observational Study. American Journal of Geriatric Psychiatry, 2011, 19, 1026-1033.	0.6	23
152	001 Long-term outcomes of patients with ST-elevation myocardial infarction with and without reperfusion therapy: Results of a systematic province-wide field evaluation in Québec. Canadian Journal of Cardiology, 2011, 27, S61.	0.8	0
153	Assessment and Management of Acute Coronary Syndromes (ACS): A Canadian Perspective on Current Guideline-Recommended Treatment – Part 2: ST-Segment Elevation Myocardial Infarction. Canadian Journal of Cardiology, 2011, 27, S402-S412.	0.8	33
154	Assessment and Management of Acute Coronary Syndromes (ACS): A Canadian Perspective on Current Guideline-Recommended Treatment $\hat{a} \in \text{Part 1: Non-ST} \in \text{Segment Elevation ACS. Canadian Journal of Cardiology, 2011, 27, S387-S401.}$	0.8	29
155	Antiplatelet and Anticoagulant Therapy in Patients With Gastrointestinal Bleeding. JAMA - Journal of the American Medical Association, 2011, 306, 2367-74.	3.8	20
156	Facioscapulohumeral Muscular Dystrophy Region Gene 1 Is a Dynamic RNA-Associated and Actin-Bundling Protein. Journal of Molecular Biology, 2011, 411, 397-416.	2.0	22
157	Review: Varenicline is better than placebo or bupropion, but not clearly different from the nicotine patch, for smoking abstinence. Annals of Internal Medicine, 2011, 154, JC4.	2.0	0
158	Review: Varenicline increases risk for serious adverse cardiovascular events in tobacco users. Annals of Internal Medicine, 2011, 155, JC4.	2.0	6
159	Analysis of Willingness to Pay for Implantable Cardioverter–Defibrillator Therapy. American Journal of Cardiology, 2011, 107, 423-427.	0.7	6
160	Routine invasive management after fibrinolysis in patients with ST-elevation myocardial infarction: a systematic review of randomized clinical trials. BMC Cardiovascular Disorders, 2011, 11, 34.	0.7	5
161	Factors associated with initiation and completion of the quadrivalent human papillomavirus vaccine series in an ontario cohort of grade 8 girls. BMC Public Health, 2011, 11, 645.	1.2	45
162	The association between drospirenone and hyperkalemia: a comparative-safety study. BMC Clinical Pharmacology, 2011, 11, 23.	2.5	20

#	Article	IF	CITATIONS
163	Thiazolidinediones and the risk of incident congestive heart failure among patients with type 2 diabetes mellitus. Pharmacoepidemiology and Drug Safety, 2011, 20, 785-796.	0.9	21
164	Willingness To Pay To Eliminate the Risk of Restenosis Following Percutaneous Coronary Intervention. Circulation: Cardiovascular Quality and Outcomes, 2011, 4, 46-52.	0.9	5
165	Oral contraceptives and the risk of gallbladder disease: a comparative safety study. Cmaj, 2011, 183, 899-904.	0.9	33
166	A model combining clinical assessment and NT-proBNP level accurately predicted heart failure in ED patients with dyspnea. Annals of Internal Medicine, 2010, 152, JC1.	2.0	1
167	Conflicting Evidence: What's a Clinician to Do?. Annals of Internal Medicine, 2010, 153, 413.	2.0	6
168	Omega-3 fatty acids in high-risk cardiovascular patients: a meta-analysis of randomized controlled trials. BMC Cardiovascular Disorders, 2010, 10, 24.	0.7	106
169	The potential interaction between clopidogrel and proton pump inhibitors: a systematic review. BMC Medicine, 2010, 8, 81.	2.3	22
170	A population-based case-control study of Selective Serotonin Reuptake Inhibitors (SSRIs) and breast cancer: The impact of duration of use, cumulative dose and latency. BMC Medicine, 2010, 8, 90.	2.3	19
171	Usefulness of Soluble Fas Levels for Improving Diagnostic Accuracy and Prognosis for Acute Coronary Syndromes. American Journal of Cardiology, 2010, 105, 797-803.	0.7	11
172	Genetic Polymorphisms and the Cardiovascular Risk of Non-Steroidal Anti-Inflammatory Drugs. American Journal of Cardiology, 2010, 105, 1740-1745.	0.7	21
173	A Comparison of Methods for Forecasting Emergency Department Visits for Respiratory Illness Using Telehealth Ontario Calls. Canadian Journal of Public Health, 2010, 101, 464-469.	1.1	9
174	Gout, Allopurinol Use, and Heart Failure Outcomes. Archives of Internal Medicine, 2010, 170, 1358.	4.3	128
175	Association Between Timeliness of Reperfusion Therapy and Clinical Outcomes in ST-Elevation Myocardial Infarction. JAMA - Journal of the American Medical Association, 2010, 303, 2148.	3.8	212
176	Therapeutic Management in Patients with Renal Failure who Experience an Acute Coronary Syndrome. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 87-94.	2.2	5
177	Statin use and risk of epilepsy. Neurology, 2010, 75, 1496-1500.	1.5	79
178	Selective Serotonin Reuptake Inhibitors and the Risk of Cataracts. Ophthalmology, 2010, 117, 1251-1255.	2.5	38
179	Contemporary Cost Analysis of Single Instillation of Mitomycin After Transurethral Resection of Bladder Tumor in a Universal Health Care System. Urology, 2010, 76, 652-656.	0.5	20
180	Recurrent Community-acquired Pneumonia in Patients Starting Acid-suppressing Drugs. American Journal of Medicine, 2010, 123, 47-53.	0.6	71

#	Article	IF	Citations
181	The disutility of restenosis $\hat{a}\in$ " the impact of repeat percutaneous coronary intervention on quality of life. Canadian Journal of Cardiology, 2010, 26, e197-e200.	0.8	4
182	Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ: British Medical Journal, 2010, 340, b5087-b5087.	2.4	859
183	Continuation of Statin Treatment and Mortality: A Note of Caution on Excessive Benefits. Archives of Internal Medicine, 2009, 169, 1069.	4.3	2
184	Routine Early Angioplasty after Fibrinolysis. New England Journal of Medicine, 2009, 361, 1507-1510.	13.9	0
185	Antipsychotic Drugs and Hyperglycemia in Older Patients With Diabetes. Archives of Internal Medicine, 2009, 169, 1282.	4.3	61
186	Adverse Outcomes Associated With Use of Proton Pump Inhibitors and Clopidogrel. JAMA - Journal of the American Medical Association, 2009, 302, 29.	3.8	5
187	The cost-effectiveness of Maze procedures using ablation techniques at the time of mitral valve surgery. International Journal of Technology Assessment in Health Care, 2009, 25, 485-496.	0.2	15
188	Microvolt T-wave alternans as a predictor of mortality and severe arrhythmias in patients with left-ventricular dysfunction: a systematic review and meta-analysis. BMC Cardiovascular Disorders, 2009, 9, 5.	0.7	15
189	Investigation of an interaction between statins and clopidogrel after percutaneous coronary intervention: a cohort study. Pharmacoepidemiology and Drug Safety, 2009, 18, 362-369.	0.9	25
190	Trends in the prescription of antiâ€diabetic medications in the United Kingdom: a populationâ€based analysis. Pharmacoepidemiology and Drug Safety, 2009, 18, 973-976.	0.9	57
191	Risk of upper gastrointestinal bleeding with oral bisphosphonates and non steroidal antiâ€inflammatory drugs: a caseâ€control study. Alimentary Pharmacology and Therapeutics, 2009, 29, 1188-1192.	1.9	23
192	Shortness of breath at night and health status in congestive heart failure: Effects of environmental conditions and health-related and dietary factors. Environmental Research, 2009, 109, 166-174.	3.7	17
193	Microvolt T-wave alternans and the selective use of implantable cardioverter defibrillators for primary prevention: A cost-effectiveness study. International Journal of Technology Assessment in Health Care, 2009, 25, 151-160.	0.2	5
194	n-3 polyunsaturated fatty acids reduced morbidity and mortality in chronic heart failure. Annals of Internal Medicine, 2009, 150, JC1.	2.0	1
195	A comparison of suicide rates between older adults in Ireland and the UK: 1975–2005. Irish Journal of Medical Science, 2008, 177, 333-337.	0.8	3
196	The interpretation of systematic reviews with meta-analyses: an objective or subjective process?. BMC Medical Informatics and Decision Making, 2008, 8, 19.	1.5	55
197	Clinical Utility of C-Reactive Protein Measured at Admission, Hospital Discharge, and 1 Month Later to Predict Outcome in Patients With Acute Coronary Disease. Journal of the American College of Cardiology, 2008, 51, 2339-2346.	1.2	70
198	Reply. Journal of the American College of Cardiology, 2008, 52, 1500-1501.	1.2	0

#	Article	IF	Citations
199	Resource allocation among cardiovascular specialists and trainees: A pilot survey. Canadian Journal of Cardiology, 2008, 24, 118-120.	0.8	O
200	A meta-analysis of antibiotic use for the secondary prevention of cardiovascular diseases. Canadian Journal of Cardiology, 2008, 24, 391-395.	0.8	33
201	Discontinuation of statin therapy following an acute myocardial infarction: a population-based study. European Heart Journal, 2008, 29, 2083-2091.	1.0	113
202	A panel study in congestive heart failure to estimate the short-term effects from personal factors and environmental conditions on oxygen saturation and pulse rate. Occupational and Environmental Medicine, 2008, 65, 659-666.	1.3	36
203	Primary PCI in ST-Segment Elevation Myocardial Infarction. New England Journal of Medicine, 2008, 358, 1751-1753.	13.9	2
204	Use of Statins and Angiotensin Converting Enzyme Inhibitors (ACE-Is) and the Risk of Age-Related Macular Degeneration: Nested Case-Control Study. Current Drug Safety, 2008, 3, 24-26.	0.3	25
205	Confounding in Database Pharmacoepidemiology Studies. Epidemiology, 2008, 19, 360-361.	1.2	6
206	Cardiovascular effects of cyclooxygenase-2 inhibitors. Current Opinion in Internal Medicine, 2008, 7, 29-36.	1.5	10
207	Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. Cmaj, 2007, 177, 347-351.	0.9	178
208	Should Meta-Analyses of Interventions Include Observational Studies in Addition to Randomized Controlled Trials? A Critical Examination of Underlying Principles. American Journal of Epidemiology, 2007, 166, 1203-1209.	1.6	383
209	Letters to the Editor. American Journal of Gastroenterology, 2007, 102, 201-221.	0.2	19
210	Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis. Cmaj, 2007, 176, 1429-1434.	0.9	113
211	Drug-eluting stents. Cmaj, 2007, 176, 1612-1613.	0.9	0
212	Has thrombolysis lost its mojo?. Heart, 2007, 93, 1167-1169.	1.2	3
213	Pravastatin and cancer: an unproven association. Cmaj, 2007, 176, 646-647.	0.9	2
214	Vaccination against human papillomavirus. Cmaj, 2007, 177, 1525-1526.	0.9	0
215	The cost-effectiveness of drug-eluting stents: a systematic review. Cmaj, 2007, 176, 199-205.	0.9	38
216	Thiazolidinediones and Cardiovascular Outcomes in Older Patients With Diabetes. JAMA - Journal of the American Medical Association, 2007, 298, 2634.	3.8	303

#	Article	IF	Citations
217	Combined antithrombotic therapy. Cmaj, 2007, 178, 327-328.	0.9	O
218	Primary data collection in health technology assessment. International Journal of Technology Assessment in Health Care, 2007, 23, 24-29.	0.2	9
219	Lack of Long-Term Benefits of a 6-Month Heart Failure Disease Management Program. Journal of Cardiac Failure, 2007, 13, 287-293.	0.7	25
220	Title is missing!. Canadian Journal of Cardiology, 2007, 23, 319.	0.8	0
221	Risk stratification following non-ST segment elevation myocardial infarction: Is the glass half-full or half-empty?. Canadian Journal of Cardiology, 2007, 23, 1080-1081.	0.8	0
222	Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis. BMC Anesthesiology, 2007, 7, 5.	0.7	18
223	The impact of over-the-counter simvastatin on the number of statin prescriptions in the United Kingdom: a view from the General Practice Research Database. Pharmacoepidemiology and Drug Safety, 2007, 16, 1-4.	0.9	51
224	Benzodiazepines and elderly drivers: a comparison of pharmacoepidemiological study designs. Pharmacoepidemiology and Drug Safety, 2007, 16, 845-849.	0.9	42
225	The Cost-Effectiveness of Stem Cell Transplantations from Unrelated Donors in Adult Patients with Acute Leukemia. Value in Health, 2007, 10, 247-255.	0.1	23
226	Lifestyle variables and the risk of myocardial infarction in the General Practice Research Database. BMC Cardiovascular Disorders, 2007, 7, 38.	0.7	27
227	Validity of electron beam computed tomography for coronary artery disease: asystematic review and meta-analysis. BMC Medicine, 2007, 5, 35.	2.3	8
228	Statin wars following coronary revascularization $\hat{a} \in \text{``Evidence-based clinical practice?'}$ . Canadian Journal of Cardiology, 2006, 22, 54-58.	0.8	8
229	Treating the right patient at the right time: Access to heart failure care. Canadian Journal of Cardiology, 2006, 22, 749-754.	0.8	82
230	Treating the right patient at the right time: Access to specialist consultation and noninvasive testing. Canadian Journal of Cardiology, 2006, 22, 819-824.	0.8	25
231	73 Asbestos disease: A Canadian case study. Lung Cancer, 2006, 54, S18.	0.9	0
232	Reduction of Morbidity and Mortality by Statins, Angiotensin-Converting Enzyme Inhibitors, and Angiotensin Receptor Blockers in Patients With Chronic Obstructive Pulmonary Disease. Journal of the American College of Cardiology, 2006, 47, 2554-2560.	1.2	357
233	A pharmacoepidemiology study of the interaction between atorvastatin and clopidogrel after percutaneous coronary intervention. American Heart Journal, 2006, 152, 263-269.	1.2	48
234	Peering at peer review revealed high degree of chance associated with funding of grant applications. Journal of Clinical Epidemiology, 2006, 59, 842-848.	2.4	57

#	Article	IF	Citations
235	Ranking Hospitals According to Acute Myocardial Infarction Mortality. Medical Care, 2006, 44, 664-670.	1.1	21
236	ACE-inhibitor use and the long-term risk of renal failure in diabetes. Kidney International, 2006, 69, 913-919.	2.6	117
237	The risk of death associated with delayed coronary artery bypass surgery. BMC Health Services Research, 2006, 6, 85.	0.9	24
238	Acute ischemic heart disease and interventional cardiology: a time for pause. BMC Medicine, 2006, 4, 25.	2.3	5
239	Do Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Decrease the Risk of Hospitalization Secondary to Community-Acquired Pneumonia? A Nested Case-Control Study. Pharmacotherapy, 2006, 26, 479-482.	1.2	19
240	Rehabilitating digoxinThe opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology European Heart Journal, 2006, 27, 127-129.	1.0	19
241	COX-2 selective drugs and cardiovascular risks: same data but discrepant conclusions?. Expert Opinion on Drug Safety, 2006, 5, 1-2.	1.0	3
242	Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors. Cmaj, 2006, 174, 1563-1569.	0.9	60
243	Association of Selective and Conventional Nonsteroidal Antiinflammatory Drugs with Acute Renal Failure: A Population-based, Nested Case-Control Analysis. American Journal of Epidemiology, 2006, 164, 881-889.	1.6	242
244	Vascular events with selective COX2 inhibitors and NSAIDs: analyzing the risks. Nature Clinical Practice Cardiovascular Medicine, 2006, 3, 586-587.	3.3	2
245	Does the Addition of Functional Status Indicators to Case-Mix Adjustment Indices Improve Prediction of Hospitalization, Institutionalization, and Death in the Elderly? Medical Care, 2005, 43, 1194-1202.	1.1	39
246	End-user involvement in health technology assessment (HTA) development: A way to increase impact. International Journal of Technology Assessment in Health Care, 2005, 21, 263-267.	0.2	113
247	The Risk for Myocardial Infarction with Cyclooxygenase-2 Inhibitors: A Population Study of Elderly Adults. Annals of Internal Medicine, 2005, 142, 481.	2.0	217
248	The Risk for Myocardial Infarction with Cyclooxygenase-2 Inhibitors. Annals of Internal Medicine, 2005, 143, 617.	2.0	1
249	Impact of care at a multidisciplinary congestive heart failure clinic: a randomized trial. Cmaj, 2005, 173, 40-45.	0.9	142
250	Selling Safety—Lessons From Muraglitazar. JAMA - Journal of the American Medical Association, 2005, 294, 2633.	3.8	18
251	Medical Decision Making with Incomplete Evidenceâ€"Choosing a Platelet Glycoprotein IIbIIIa Receptor Inhibitor for Percutaneous Coronary Interventions. Medical Decision Making, 2005, 25, 222-228.	1.2	8
252	Cardiovascular Risk Associated with Celecoxib. New England Journal of Medicine, 2005, 352, 2648-2650.	13.9	29

#	Article	IF	CITATIONS
253	The dollars and sense of drug-eluting stents. Cmaj, 2005, 172, 361-362.	0.9	10
254	Celecoxib and cardiovascular risks. Expert Opinion on Drug Safety, 2005, 4, 1005-1015.	1.0	51
255	Fluctuating Inflammatory Markers in Patients With Stable Ischemic Heart Disease. Archives of Internal Medicine, 2005, 165, 221.	4.3	69
256	Physicians' attitudes to the pharmacological treatment of patients with stable angina pectoris. QJM - Monthly Journal of the Association of Physicians, 2005, 98, 41-51.	0.2	14
257	GRACIA: implications for clinical practice. Lancet, The, 2005, 365, 381.	6.3	2
258	Numbers needed to treat (needlessly?). Lancet, The, 2005, 365, 1307-1308.	6.3	17
259	Cost-effectiveness of drug-eluting coronary stents in Quebec, Canada. International Journal of Technology Assessment in Health Care, 2005, 21, 326-333.	0.2	23
260	The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction. Heart, 2005, 93, 189-194.	1.2	57
261	Follow-up of an intervention program for caregivers of a relative with dementia living in a long-term care setting: Are there any persistent and delayed effects?. Aging and Mental Health, 2005, 9, 461-469.	1.5	19
262	The benefit of cholesterol-lowering medications after coronary revascularization: A population study. American Heart Journal, 2005, 150, 282-286.	1.2	8
263	Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review. Cmaj, 2005, 173, 167-170.	0.9	174
264	Primary Angioplasty and Thrombolysis Are Both Reasonable Options in Acute Myocardial Infarction. Annals of Internal Medicine, 2004, 141, 292.	2.0	14
265	Primary angioplasty or thrombolysis? a topical parable. BMJ: British Medical Journal, 2004, 328, 1257-1258.	2.4	1
266	Impact of Prolonged Cyclooxygenase-2 Inhibition on Inflammatory Markers and Endothelial Function in Patients With Ischemic Heart Disease and Raised C-Reactive Protein. Circulation, 2004, 110, 934-939.	1.6	97
267	Routine clinical variables predicted mortality in patients with heart failure and systolic dysfunction. Evidence-Based Medicine, 2004, 9, 154-154.	0.6	0
268	Variability of breast cancer risk in observational studies of hormone replacement therapy: a meta-regression analysis. Maturitas, 2004, 47, 175-183.	1.0	12
269	A multivariate model for predicting mortality in patients with heart failure and systolic dysfunction. American Journal of Medicine, 2004, $116$ , $300-304$ .	0.6	127
270	A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet, The, 2004, 364, 583-591.	6.3	597

#	Article	IF	CITATIONS
271	Drug treatment of stable angina pectoris and mass dissemination of therapeutic guidelines: a randomized controlled trial. QJM - Monthly Journal of the Association of Physicians, 2004, 97, 21-31.	0.2	17
272	Antibiotics in primary prevention of myocardial infarction among elderly patients with hypertension. American Heart Journal, 2003, 145, 918.	1.2	8
273	Increasing burden of treatment in the acute coronary syndromes: is it justified?. Lancet, The, 2003, 361, 1813-1816.	6.3	12
274	The EUROPA trial. Lancet, The, 2003, 362, 1936.	6.3	0
275	Maintaining exercise involvement: the role of learned resourcefulness in process of change use. Psychology of Sport and Exercise, 2003, 4, 237-253.	1.1	12
276	Misplaced pacemaker wire as a cause of mitral regurgitation. British Heart Journal, 2003, 89, 246-246.	2.2	0
277	Absence of Association Between Infectious Agents and Endothelial Function in Healthy Young Men. Circulation, 2003, 107, 1966-1971.	1.6	56
278	Antibiotics in Primary Prevention of Stroke in the Elderly. Stroke, 2003, 34, e163-6.	1.0	17
279	Evidence for Use of Coronary Stents: A Hierarchical Bayesian Meta-Analysis. Annals of Internal Medicine, 2003, 138, 777.	2.0	167
280	The use of cholesterol-lowering medications after coronary revascularization. Cmaj, 2003, 169, 1153-7.	0.9	1
281	Expression of kinin B1 receptor in fresh or cultured rabbit aortic smooth muscle: role of NF-κB. American Journal of Physiology - Heart and Circulatory Physiology, 2002, 283, H227-H237.	1.5	37
282	Effects of Radiation Therapy on Vascular Responsiveness. Journal of Cardiovascular Pharmacology, 2001, 37, 381-393.	0.8	13
283	Î <sup>2</sup> -Blockers in Congestive Heart Failure: A Bayesian Meta-Analysis. Annals of Internal Medicine, 2001, 134, 550.	2.0	347
284	Are patients suffering from stable angina receiving optimal medical treatment?. QJM - Monthly Journal of the Association of Physicians, 2001, 94, 301-308.	0.2	25
285	Resolution of allelic and non-allelic variants of histone H1 by cation-exchange-hydrophilic-interaction chromatography. Biomedical Applications, 2000, 744, 33-46.	1.7	30
286	Improved Clinical Outcome after Widespread Use of Coronary-Artery Stenting in Canada. New England Journal of Medicine, 2000, 342, 1448-1449.	13.9	2
287	Long-term ACE-inhibitor therapy. Lancet, The, 2000, 356, 338.	6.3	3
288	Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet, The, 2000, 355, 253-259.	6.3	3,134

#	Article	IF	Citations
289	Presenilin structure, function and role in Alzheimer disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2000, 1502, 1-15.	1.8	83
290	Medical Decision Making in the Choice of a Thrombolytic Agent for Acute Myocardial Infarction. Medical Decision Making, 1999, 19, 411-418.	1.2	3
291	Identification of an NTF2-Related Factor That Binds Ran-GTP and Regulates Nuclear Protein Export. Molecular and Cellular Biology, 1999, 19, 8616-8624.	1.1	88
292	Determining Appropriateness of Coronary Thrombolysis in the Emergency Department. Annals of Emergency Medicine, 1998, 31, 12-18.	0.3	2
293	Enthusiasm, reality, and cost-effectiveness analysis. Heart, 1998, 79, 9-10.	1.2	4
294	Thrombolytic Therapy for Myocardial Infarction. New England Journal of Medicine, 1998, 338, 545-548.	13.9	2
295	Gender Differences in Management of Myocardial Infarction in Quebec. Journal of the American College of Cardiology, 1998, 31, 308A.	1.2	0
296	The Effect of Digoxin on Mortality and Morbidity in Patients with Heart Failure. New England Journal of Medicine, 1997, 336, 525-533.	13.9	2,690
297	Bayesian interim analysis of randomised trials. Lancet, The, 1997, 349, 1911.	6.3	0
298	Bayesian interim statistical analysis of randomised trials. Lancet, The, 1997, 349, 1166-1168.	6.3	13
299	The long term prognosis in patients following thrombolysis for acute myocardial infarction: a view from a community hospital. International Journal of Cardiology, 1997, 55, 277-283.	0.8	0
300	The long term prognosis in patients following thrombolysis for acute myocardial infarction: a view from a community hospital. International Journal of Cardiology, 1996, 55, 277-283.	0.8	1
301	Rationale, design, implementation, and baseline characteristics of patients in the dig trial: A large, simple, long-term trial to evaluate the effect of digitalis on mortality in heart failure. Contemporary Clinical Trials, 1996, 17, 77-97.	2.0	127
302	Development of a binding assay for the B1 receptors for kinins. Immunopharmacology, 1995, 29, 141-147.	2.0	36
303	Placing trials in context using bayesian analysis: GUSTO revisited by Reverend Bayes. ACC Current Journal Review, 1995, 4, 72.	0.1	0
304	Placing Trials in Context Using Bayesian Analysis. JAMA - Journal of the American Medical Association, 1995, 273, 871.	3.8	116
305	Bayesian Analysis and the GUSTO Trial-Reply. JAMA - Journal of the American Medical Association, 1995, 274, 874.	3.8	0
306	Quality of Life after Myocardial Infarction: Canada versus the United States. New England Journal of Medicine, 1995, 332, 469-472.	13.9	3

#	Article	IF	CITATIONS
307	Regulation of kininâ€induced contraction and DNA synthesis by inflammatory cytokines in the smooth muscle of the rabbit aorta. British Journal of Pharmacology, 1995, 116, 1673-1679.	2.7	31
308	Placing trials in context using Bayesian analysis. GUSTO revisited by Reverend Bayes. JAMA - Journal of the American Medical Association, 1995, 273, 871-875.	3.8	80
309	Fortnightly Review: Diagnosis and management of heart failure. BMJ: British Medical Journal, 1994, 308, 321-328.	2.4	136
310	The Saskatchewan oral contraceptive cohort study of oral contraceptive use and cardiovascular risks. Pharmacoepidemiology and Drug Safety, 1993, 2, 33-49.	0.9	8
311	Thrombolytic therapy for myocardial infarction. Annals of Emergency Medicine, 1988, 17, 760.	0.3	O
312	Diabetes and Atrial Fibrillation: Does the type of diabetes matter? European Journal of Preventive Cardiology, $0, , .$	0.8	0